SC
ACAD icon

SMA Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

SMA Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Buy
+412
New +$9.06K ﹤0.01% 107

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SMA Capital's ACAD Position: Q2 2026 in Review

SMA Capital opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 412 shares worth $10.4K. The stake represents ﹤0.01% of the portfolio and ranks #107 among its holdings.

352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • SMA Capital held 412 shares of Acadia Pharmaceuticals worth $10.4K as of Q2 2026.
  • Acadia Pharmaceuticals was a new SMA Capital position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of SMA Capital's portfolio in Q2 2026, its #107 holding.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.